一个随机的可行性试验中链甘油三补充基因饮食在帕金森病患者中
Alexander H Choi1,2, Melanie Delgado3, Kong Y Chen4
1National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, MD, USA. choi.alexander7@gmail.com.
BMC neurology
|April 2, 2024
概括
一种性饮食 (KD) 补充中链甘油 (MCT) 油是可行的和可接受的帕金森病 (PD) 患者. 需要进一步的研究来证实它对PD症状和疾病进展的影响.
科学领域:
- 神经科学是一个神经科学.
- 代谢障碍 代谢障碍 代谢障碍
- 营养科学 营养科学
背景情况:
- 帕金森病 (PD) 是一种神经退行性疾病,可能与线粒体功能障碍有关.
- 性饮食 (KD) 可能为涉及线粒体问题的疾病提供治疗益处.
研究的目的:
- 在帕金森病 (PD) 患者中评估中链甘油三补充性饮食 (MCT-KD) 的可行性和可接受性.
- 探索MCT-KD对PD各种临床和生理标志物的影响.
主要方法:
- 一个随机的,双盲的,安慰剂控制的试验,将MCT-KD与标准饮食 (SD) 进行一周的比较,随后进行为期两周的开放式延长.
- 主要结局包括KD可行性和可接受性;次要结局涉及定时升级和启动 (TUG) 测试.
- 探索性结果包括认知测试,症状尺度和静止电脑图 (rsEEG).
主要成果:
- 在16名PD患者中,MCT-KD对15名PD患者来说是可行的和可以接受的.
- 在MCT-KD和SD组之间没有观察到TUG时间的显著差异.
- 到第3周,非运动性症状的严重程度显著下降,特别是在MCT-KD组.
- 在MCT-KD组中,血症在第4天实现.
结论:
- 补充MCT油的性饮食是帕金森病患者可行的和可接受的饮食干预措施.
- 虽然初步结果对非运动性症状有希望,但需要进一步的研究来充分阐明MCT-KD在PD中的治疗潜力.
相关概念视频
Parkinson's Disease: Treatment
264
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
264
Parkinson's Disease: Overview
541
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
541


